Skip to main content
Erschienen in: Strahlentherapie und Onkologie 5/2013

01.05.2013 | Original article

125I Seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents

verfasst von: L. Zheng, MD, DDS, J. Zhang, MD, DDS, T. Song, MD, DDS, Prof. J. Zhang, MD, DDS, G. Yu, MD, DDS, Y. Zhang, MD, DDS

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

There is a lack of optimal treatment strategies for managing salivary gland cancers in children and adolescents. This study is aimed at assessing the effect of 125I seed implantation for the treatment of parotid cancers in children and adolescents.

Patients and methods

A total of 12 patients younger than 16 years with parotid gland malignant tumors underwent 125I seed implant brachytherapy between October 2003 and November 2008. All patients were assessed after treatment and at the local tumor control appointments. Facial nerve function, maxillofacial development, and radioactive side-effects were assessed.

Results

The follow-up period ranged from 41–104 months. One patient with T4b died of pulmonary metastasis. The other patients were alive during the follow-up period. There were no serious radiation-related complications. The treatment did not affect facial nerve function and dentofacial growth in any of the children.

Conclusion

For parotid gland cancers in children, 125I seed implant brachytherapy may be an acceptable treatment without serious complications and with satisfactory short-term effects.
Literatur
1.
Zurück zum Zitat Greer RO, Mierau GW, Favara BE (1983) Tumors of the head and neck in children. Praeger Publishers, New York, p 166 Greer RO, Mierau GW, Favara BE (1983) Tumors of the head and neck in children. Praeger Publishers, New York, p 166
2.
Zurück zum Zitat Shikhani AH, Johns ME (1988) Tumors of major salivary glands in children. Head Neck Surg 10:257–263PubMed Shikhani AH, Johns ME (1988) Tumors of major salivary glands in children. Head Neck Surg 10:257–263PubMed
3.
Zurück zum Zitat Rogers DA, Rao BN, Bowman L et al (1994) Primary malignancy of the salivary gland in children. J Pediatr Surg 29:44–47CrossRefPubMed Rogers DA, Rao BN, Bowman L et al (1994) Primary malignancy of the salivary gland in children. J Pediatr Surg 29:44–47CrossRefPubMed
4.
Zurück zum Zitat Rush BF, Chambers RG, Rovitch MM (1963) Cancer of the head and neck in children. Surgery 53:270–284PubMed Rush BF, Chambers RG, Rovitch MM (1963) Cancer of the head and neck in children. Surgery 53:270–284PubMed
5.
Zurück zum Zitat Seifert G, Okabe H, Caselitz J et al (1986) Epithelial salivary gland tumors in children and adolescents. Analysis of 80 cases (Salivary Gland Register 1965–1984). J Otorhinolaryngol Relat Spec 48:137–149CrossRef Seifert G, Okabe H, Caselitz J et al (1986) Epithelial salivary gland tumors in children and adolescents. Analysis of 80 cases (Salivary Gland Register 1965–1984). J Otorhinolaryngol Relat Spec 48:137–149CrossRef
6.
Zurück zum Zitat Ellies M, Scbaffranietz F, Arglebe C, Laskawi R (2006) Tumors of the salivary glands in childhood and adolescence. J Oral Maxillofac Surg 64:1049–1058CrossRefPubMed Ellies M, Scbaffranietz F, Arglebe C, Laskawi R (2006) Tumors of the salivary glands in childhood and adolescence. J Oral Maxillofac Surg 64:1049–1058CrossRefPubMed
7.
Zurück zum Zitat Callender DL, Frankenthaler RA, Luna MA et al (1992) Salivary gland neoplasms in children. Arch Otolaryngol Head Neck Surg 118:472–476CrossRefPubMed Callender DL, Frankenthaler RA, Luna MA et al (1992) Salivary gland neoplasms in children. Arch Otolaryngol Head Neck Surg 118:472–476CrossRefPubMed
8.
Zurück zum Zitat Kessler A, Handler SD (1994) Salivary gland neoplasms in children: a 10 year survey at the children’s hospital of Philadelphia. Int J Pediatr Otorhinolaryngol 29:195–202CrossRefPubMed Kessler A, Handler SD (1994) Salivary gland neoplasms in children: a 10 year survey at the children’s hospital of Philadelphia. Int J Pediatr Otorhinolaryngol 29:195–202CrossRefPubMed
9.
Zurück zum Zitat Zhang J, Zhang JG, Song TL et al (2008) 125I seed implant brachytherapy-assisted surgery with preservation of the facial nerve for treatment of malignant parotid gland tmors. Int J Oral Maxillofac Surg 37:515–520CrossRefPubMed Zhang J, Zhang JG, Song TL et al (2008) 125I seed implant brachytherapy-assisted surgery with preservation of the facial nerve for treatment of malignant parotid gland tmors. Int J Oral Maxillofac Surg 37:515–520CrossRefPubMed
10.
Zurück zum Zitat Services U.S. Department of Health (2003) Common terminology criteria for adverse events (CTCAE): version 3.0. National Institutes of Health National Cancer Institute Services U.S. Department of Health (2003) Common terminology criteria for adverse events (CTCAE): version 3.0. National Institutes of Health National Cancer Institute
11.
Zurück zum Zitat Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13:7–16CrossRefPubMed Harish K (2004) Management of primary malignant epithelial parotid tumors. Surg Oncol 13:7–16CrossRefPubMed
13.
Zurück zum Zitat Yu GY, Li ZL, Ma DQ, Zhang Y (2002) Diagnosis and treatment of epithelial salivary gland tumours in children and adolescents. Br J Oral Maxillofac Surg 40:389–392PubMed Yu GY, Li ZL, Ma DQ, Zhang Y (2002) Diagnosis and treatment of epithelial salivary gland tumours in children and adolescents. Br J Oral Maxillofac Surg 40:389–392PubMed
14.
Zurück zum Zitat Ribeiro Kde C, Kowalski LP, Saba LM, Camargo B de (2002) Epithelial salivary glands neoplasms in children and adolescents: a forty-four-year experience. Med Pediatr Oncol 39:594–600CrossRef Ribeiro Kde C, Kowalski LP, Saba LM, Camargo B de (2002) Epithelial salivary glands neoplasms in children and adolescents: a forty-four-year experience. Med Pediatr Oncol 39:594–600CrossRef
15.
Zurück zum Zitat Garden AS, el-Nagger AK, Morrison WH et al (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Bio Phys 37:79–85CrossRef Garden AS, el-Nagger AK, Morrison WH et al (1997) Postoperative radiotherapy for malignant tumors of the parotid gland. Int J Radiat Oncol Bio Phys 37:79–85CrossRef
16.
Zurück zum Zitat Milanovic D, Jeremic B, Kayser G et al (2012) Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade. Strahlenther Onkol 188:518–522CrossRefPubMed Milanovic D, Jeremic B, Kayser G et al (2012) Relapsing high grade mucoepidermoid carcinoma. Long-lasting complete response following reirradiation and EGFR blockade. Strahlenther Onkol 188:518–522CrossRefPubMed
17.
Zurück zum Zitat Kubes J, Cvek J, Vondracek V et al (2011) Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks): an alternative in the treatment of locally advanced head and neck cancer. Strahlenther Onkol 187:651–655CrossRefPubMed Kubes J, Cvek J, Vondracek V et al (2011) Accelerated radiotherapy with concomitant boost technique (69.5 Gy/5 weeks): an alternative in the treatment of locally advanced head and neck cancer. Strahlenther Onkol 187:651–655CrossRefPubMed
18.
Zurück zum Zitat Bell RB, Dierks EJ, Homer L, Potter BE (2005) Management and outcome of patients with malignant salivary gland tumors. Int J Oral Maxillofac Surg 63:917–928CrossRef Bell RB, Dierks EJ, Homer L, Potter BE (2005) Management and outcome of patients with malignant salivary gland tumors. Int J Oral Maxillofac Surg 63:917–928CrossRef
19.
Zurück zum Zitat Gurney TA, Eisele DW, Weinberg V et al (2005) Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 115:1278–1282CrossRefPubMed Gurney TA, Eisele DW, Weinberg V et al (2005) Adenoid cystic carcinoma of the major salivary glands treated with surgery and radiation. Laryngoscope 115:1278–1282CrossRefPubMed
20.
Zurück zum Zitat Nag S, Beyer D, Friedland J et al (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789–799CrossRefPubMed Nag S, Beyer D, Friedland J et al (1999) American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 44:789–799CrossRefPubMed
21.
Zurück zum Zitat Langley SE, Laing R (2002) Prostate brachytherapy has come of age: a review of the technique and results. BJU Int 89:241–249CrossRefPubMed Langley SE, Laing R (2002) Prostate brachytherapy has come of age: a review of the technique and results. BJU Int 89:241–249CrossRefPubMed
22.
Zurück zum Zitat Nag S, Ribovich M, Zhan Cai J, Wientjes MG (1996) Palladium-103 vs iodine-125 brachytherapy in the Dunning-PAP rat prostate tumor. Endocuriether Hypertherm Oncol 12:119–124 Nag S, Ribovich M, Zhan Cai J, Wientjes MG (1996) Palladium-103 vs iodine-125 brachytherapy in the Dunning-PAP rat prostate tumor. Endocuriether Hypertherm Oncol 12:119–124
23.
Zurück zum Zitat Nag S, Sweeney PJ, Wientjes MG (1993) Dose-response study of iodine-125 and palladium-103 brachytherapy in a rat prostate tumor (Nb AI-1). Endocuriether Hypertherm Oncol 9:97–104 Nag S, Sweeney PJ, Wientjes MG (1993) Dose-response study of iodine-125 and palladium-103 brachytherapy in a rat prostate tumor (Nb AI-1). Endocuriether Hypertherm Oncol 9:97–104
24.
Zurück zum Zitat Zbären P, Nuyens M, Caversaccio M et al (2006) Postoperative radiation therapy for T1 and T2 primary parotid gland carcinoma: is it useful? Otolaryngol Head Neck Surg 135:140–143CrossRefPubMed Zbären P, Nuyens M, Caversaccio M et al (2006) Postoperative radiation therapy for T1 and T2 primary parotid gland carcinoma: is it useful? Otolaryngol Head Neck Surg 135:140–143CrossRefPubMed
25.
Zurück zum Zitat Vathaire F de, Francois P, Hill C et al (1989) Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 59:792–796CrossRefPubMed Vathaire F de, Francois P, Hill C et al (1989) Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer 59:792–796CrossRefPubMed
26.
Zurück zum Zitat Kony SJ, Vathaire F de, Chompret A et al (1997) Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood [see comments]. Lancet 350:91–95CrossRefPubMed Kony SJ, Vathaire F de, Chompret A et al (1997) Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood [see comments]. Lancet 350:91–95CrossRefPubMed
27.
Zurück zum Zitat Moppett J, Oakhill A, Duncan AW (2001) Second malignancies in children: the usual suspects? Eur J Radiol 38:235–248CrossRefPubMed Moppett J, Oakhill A, Duncan AW (2001) Second malignancies in children: the usual suspects? Eur J Radiol 38:235–248CrossRefPubMed
Metadaten
Titel
125I Seed implant brachytherapy for the treatment of parotid gland cancers in children and adolescents
verfasst von
L. Zheng, MD, DDS
J. Zhang, MD, DDS
T. Song, MD, DDS
Prof. J. Zhang, MD, DDS
G. Yu, MD, DDS
Y. Zhang, MD, DDS
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Strahlentherapie und Onkologie / Ausgabe 5/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI
https://doi.org/10.1007/s00066-013-0313-6

Weitere Artikel der Ausgabe 5/2013

Strahlentherapie und Onkologie 5/2013 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.